Asthma & COPD Medications

There is general agreement that chronic obstructive pulmonary disease. (COPD) is a global epidemic affecting both developed and, particularly, developing countries.

Despite access to the most up-to-date medicine currently available. We all also agree that its management is inadequate in at least two ways; people still smoke cigarettes and, for those who already have COPD, current treatment is inadequate. Patients still suffer and die of COPD.

None of our therapies have substantially decreased its mortality or progression in this disease.

Although effective therapies are available for asthma, the disease in many patients is not adequately controlled.

The asthma–COPD overlap syndrome combines the suffering and mortality of both disorders and may require combined therapy.

From this Perspective we focus on the drugs currently being developed to address these unmet needs.

The same drug classes are often in development for severe asthma and COPD in parallel, as there are many shared mechanisms of chronic inflammation.

Additionally in asthma, the greatest need, apart from improving adherence, is the need for therapies that address patients who have severe disease despite using current therapies.

In COPD the greatest needs are for treatments that address smoking cessation and the underlying progressive disease process that can continue to damage the airways and parenchyma long after smoking cessation.

Types of Therapies

Bronchodilators

Although short-acting inhaled bronchodilators (such as albuterol and ipratropium) are still used as rescue therapy, the major development has been in the introduction of long-acting inhaled β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), with several new products and LABA–LAMA combinations now on the market and in clinical development.

Triple Inhalers

Fixed combinations of ICS–LABA–LAMA are now in development for COPD and severe asthma. One of the first triple inhalers with beclomethasone dipropionate–formoterol–glycopyrrolate twice daily shows a clinical advantage over the ICS–LABA combination in patients with COPD.

Muscarinic Antagonists

Muscarinic antagonist–β2 agonists (MABAs), combining two pharmacophores by an inactive spine, are also in development.

A major problem is that it is difficult to balance the LABA and LAMA activities. So that most MABAs tend to have a predominance of either LABA or LAMA activity.

MABAs combined with an ICS are also in development as functional triple combinations.

Inhaled Corticosteriods

Several ICSs for twice-daily administration are now on the market and a once-daily ICS, fluticasone furoate, has been introduced in combination with vilanterol. There has been a search for safer corticosteroids and several nonsteroidal selective glucocorticoid receptor agonists (SEGRAs).

Phosphodiesterase Inhibitors

The discovery that the bronchodilator and antiinflammatory effects of theophylline are mediated mainly through inhibition of phosphodiesterases (PDEs), which include 11 major families of enzyme, each of which may have several isoforms, led to the development of selective PDE inhibitors in the hope that efficacy may be enhanced and side effects reduced.

Showing 1–20 of 58 results

  • Placeholder
    Ampoule

    XOLAIR 150 MG 2 ML 1 AMP

    2,700.00 EGP
  • ULTIBRO BREEZHALER 110/50MG 30CAP
    Asthma & COPD Medications

    ULTIBRO BREEZHALER 110/50MG 30CAP

    550.25 EGP
  • Asthma & COPD Medications

    FLUTIFORM 250MG/10MG INHALER

    481.00 EGP
  • SPIRIVA RESPIMAT 2.5 MICROGRAM 4ML
    Asthma & COPD Medications

    SPIRIVA RESPIMAT 2.5 MICROGRAM 4ML

    416.00 EGP
  • SPIRIVA 18MCG 30CAP +جهاز
    Asthma & COPD Medications

    SPIRIVA 18MCG 30CAP +جهاز

    416.00 EGP
  • Placeholder
    Asthma & COPD Medications

    FLUTIFORM 125MG/5MH INHALER

    318.00 EGP
  • Asthma & COPD Medications

    FOSTER SOLUTION

    Rated 0 out of 5
    291.25 EGP
  • SEEBRI BREEZHALER 30 CAP
    Asthma & COPD Medications

    SEEBRI BREEZHALER 30 CAP

    260.00 EGP
  • FLUTIFORM 50MG/5MG INHALER
    Asthma & COPD Medications

    FLUTIFORM 50MG/5MG INHALER

    249.00 EGP
  • SYMBICORT 320IU TURBUHALER
    Asthma & COPD Medications

    SYMBICORT 320IU TURBUHALER

    182.00 EGP
  • SYMBICORT TURBUHALER 160/120DOSES
    Asthma & COPD Medications

    SYMBICORT TURBUHALER 160/120DOSES

    170.00 EGP
  • Placeholder
    Asthma & COPD Medications

    SERETIDE DISKUS 250-60DOSE $

    168.00 EGP
  • Placeholder
    Asthma & COPD Medications

    WESTABREATH 20 TAB

    160.00 EGP
  • FORADIL CAP
    Asthma & COPD Medications

    FORADIL CAP

    141.00 EGP
  • SYMBICORT 160IU TURBUHALER
    Asthma & COPD Medications

    SYMBICORT 160IU TURBUHALER

    133.00 EGP
  • SYMBICORT 80IU TURBUHALER
    Asthma & COPD Medications

    SYMBICORT 80IU TURBUHALER

    126.00 EGP
  • Asthma & COPD Medications

    COMBIVENT VIALS 20 UIT 2.5ML

    Rated 0 out of 5
    100.00 EGP
  • Placeholder
    Asthma & COPD Medications

    FORMOHALE 30 CAP

    92.50 EGP
  • SWABIVENT 500MG 20 AMP
    Ampoule

    SWABIVENT 500MG 20 AMP

    89.75 EGP
  • FLIXOTIDE DISKUS 250MCG
    Asthma & COPD Medications

    FLIXOTIDE DISKUS 250MCG

    85.00 EGP
Shopping Cart

Filter by price

Brand

All 123 a b c d e f g h i j k l m n o p q r s t u v w x y z
Don`t copy text!
Scroll to Top
Open chat